TipRanks
Immunome (IMNM)
NASDAQ:IMNM
US Market
IMNM
Immunome
RESEARCH TOOLSreports
Want to see IMNM full AI Analyst Report?

Immunome (IMNM) Stock Forecast & Price Target

466 Followers
See the Price Targets and Ratings of:

IMNM Analyst Ratings

Strong Buy
13Ratings
Strong Buy
12 Buy
1 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Immunome
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IMNM Stock 12 Month Forecast

Average Price Target

$35.33
▲(20.26% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Immunome in the last 3 months. The average price target is $35.33 with a high forecast of $40.00 and a low forecast of $24.00. The average price target represents a 20.26% change from the last price of $29.38.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","41":"$41","17.75":"$17.75","25.5":"$25.5","33.25":"$33.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.333333333333336,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,17.75,25.5,33.25,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.89,22.36,23.830000000000002,25.3,26.77,28.240000000000002,29.71,31.18,32.65,34.120000000000005,35.59,37.06,38.53,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.89,22.00102564102564,23.112051282051283,24.223076923076924,25.334102564102565,26.445128205128206,27.556153846153848,28.66717948717949,29.77820512820513,30.88923076923077,32.00025641025641,33.11128205128205,34.222307692307695,{"y":35.333333333333336,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.89,21.12923076923077,21.36846153846154,21.607692307692307,21.846923076923076,22.086153846153845,22.325384615384614,22.564615384615387,22.803846153846155,23.043076923076924,23.282307692307693,23.521538461538462,23.76076923076923,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.34,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.32,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.48,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.14,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.21,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.73,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.78,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.49,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.76,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.065,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.89,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$40.00Average Price Target$35.33Lowest Price Target$24.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on IMNM
Sharon Zackfia
William Blair
William Blair
$35
Buy
19.13%
Upside
Initiated
10/15/26
Immunome initiated with an Outperform at William BlairImmunome initiated with an Outperform at William Blair
Stifel Nicolaus Analyst forecast on IMNM
Dara Azar
Stifel Nicolaus
Stifel Nicolaus
$24
Hold
-18.31%
Downside
Reiterated
10/06/26
Immunome (IMNM) Gets a Hold from Stifel Nicolaus
LifeSci Capital Analyst forecast on IMNM
Charles Zhu
LifeSci Capital
LifeSci Capital
$40
Buy
36.15%
Upside
Reiterated
10/05/26
Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Pacira Pharmaceuticals (PCRX)
Barclays Analyst forecast on IMNM
Lukas Shumway
Barclays
Barclays
$36
Buy
22.53%
Upside
Reiterated
10/01/26
Barclays Remains a Buy on Immunome (IMNM)
Alliance Global Partners Analyst forecast on IMNM
Matthew Venezia
Alliance Global Partners
Alliance Global Partners
$32
Buy
8.92%
Upside
Initiated
09/21/26
Immunome initiated with a Buy at Alliance GlobalImmunome initiated with a Buy at Alliance Global
H.C. Wainwright Analyst forecast on IMNM
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$40
Buy
36.15%
Upside
Reiterated
09/11/26
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (NASDAQ: FTRE) and Immunome (NASDAQ: IMNM)
Wedbush Analyst forecast on IMNM
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$31→$35
Buy
19.13%
Upside
Reiterated
08/12/26
Wedbush Sticks to Their Buy Rating for Immunome (IMNM)
Guggenheim Analyst forecast on IMNM
Michael Schmidt
Guggenheim
Guggenheim
$35
Buy
19.13%
Upside
Reiterated
08/12/26
Immunome (IMNM) Receives a Buy from Guggenheim
Evercore ISI Analyst forecast on IMNM
Cory Kasimov
Evercore ISI
Evercore ISI
$40
Buy
36.15%
Upside
Reiterated
08/12/26
Evercore ISI Remains a Buy on Immunome (IMNM)
Piper Sandler Analyst forecast on IMNM
Biren Amin
Piper Sandler
Piper Sandler
$33
Buy
12.32%
Upside
Reiterated
08/12/26
Piper Sandler Keeps Their Buy Rating on Immunome (IMNM)
Craig-Hallum Analyst forecast on IMNM
Adam Vogel
Craig-Hallum
Craig-Hallum
$36
Buy
22.53%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (NASDAQ: FENC) and Immunome (NASDAQ: IMNM)
Truist Financial Analyst forecast on IMNM
Supawat Thongthip
Truist Financial
Truist Financial
$37→$38
Buy
29.34%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Maze Therapeutics, Inc. (NASDAQ: MAZE) and Immunome (NASDAQ: IMNM)
TD Cowen Analyst forecast on IMNM
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
J.P. Morgan Analyst forecast on IMNM
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/29/26
Analyst Brian Cheng Initiates Buy on Immunome, Citing Differentiated Pipeline and Compelling Risk‑Reward Profile
Lake Street Analyst forecast on IMNM
Chad Messer
Lake Street
Lake Street
$30
Buy
2.11%
Upside
Reiterated
06/01/26
Lake Street Remains a Buy on Immunome (IMNM)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on IMNM
Sharon Zackfia
William Blair
William Blair
$35
Buy
19.13%
Upside
Initiated
10/15/26
Immunome initiated with an Outperform at William BlairImmunome initiated with an Outperform at William Blair
Stifel Nicolaus Analyst forecast on IMNM
Dara Azar
Stifel Nicolaus
Stifel Nicolaus
$24
Hold
-18.31%
Downside
Reiterated
10/06/26
Immunome (IMNM) Gets a Hold from Stifel Nicolaus
LifeSci Capital Analyst forecast on IMNM
Charles Zhu
LifeSci Capital
LifeSci Capital
$40
Buy
36.15%
Upside
Reiterated
10/05/26
Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Pacira Pharmaceuticals (PCRX)
Barclays Analyst forecast on IMNM
Lukas Shumway
Barclays
Barclays
$36
Buy
22.53%
Upside
Reiterated
10/01/26
Barclays Remains a Buy on Immunome (IMNM)
Alliance Global Partners Analyst forecast on IMNM
Matthew Venezia
Alliance Global Partners
Alliance Global Partners
$32
Buy
8.92%
Upside
Initiated
09/21/26
Immunome initiated with a Buy at Alliance GlobalImmunome initiated with a Buy at Alliance Global
H.C. Wainwright Analyst forecast on IMNM
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$40
Buy
36.15%
Upside
Reiterated
09/11/26
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (NASDAQ: FTRE) and Immunome (NASDAQ: IMNM)
Wedbush Analyst forecast on IMNM
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$31→$35
Buy
19.13%
Upside
Reiterated
08/12/26
Wedbush Sticks to Their Buy Rating for Immunome (IMNM)
Guggenheim Analyst forecast on IMNM
Michael Schmidt
Guggenheim
Guggenheim
$35
Buy
19.13%
Upside
Reiterated
08/12/26
Immunome (IMNM) Receives a Buy from Guggenheim
Evercore ISI Analyst forecast on IMNM
Cory Kasimov
Evercore ISI
Evercore ISI
$40
Buy
36.15%
Upside
Reiterated
08/12/26
Evercore ISI Remains a Buy on Immunome (IMNM)
Piper Sandler Analyst forecast on IMNM
Biren Amin
Piper Sandler
Piper Sandler
$33
Buy
12.32%
Upside
Reiterated
08/12/26
Piper Sandler Keeps Their Buy Rating on Immunome (IMNM)
Craig-Hallum Analyst forecast on IMNM
Adam Vogel
Craig-Hallum
Craig-Hallum
$36
Buy
22.53%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (NASDAQ: FENC) and Immunome (NASDAQ: IMNM)
Truist Financial Analyst forecast on IMNM
Supawat Thongthip
Truist Financial
Truist Financial
$37→$38
Buy
29.34%
Upside
Reiterated
08/12/26
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Maze Therapeutics, Inc. (NASDAQ: MAZE) and Immunome (NASDAQ: IMNM)
TD Cowen Analyst forecast on IMNM
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
J.P. Morgan Analyst forecast on IMNM
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/29/26
Analyst Brian Cheng Initiates Buy on Immunome, Citing Differentiated Pipeline and Compelling Risk‑Reward Profile
Lake Street Analyst forecast on IMNM
Chad Messer
Lake Street
Lake Street
$30
Buy
2.11%
Upside
Reiterated
06/01/26
Lake Street Remains a Buy on Immunome (IMNM)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
HROWHarrow Health
KURAKura Oncology
DNLIDenali Therapeutics
STOKStoke Therapeutics
CELCCelcuity
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Immunome

3 Months
Chad MesserLake Street
Success Rate
7/9 ratings generated profit
78%
Average Return
+18.04%
Copying Chad Messer's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +18.04% per trade.
1 Year
Cory KasimovEvercore ISI
Success Rate
3/7 ratings generated profit
43%
Average Return
+30.24%
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +30.24% per trade.
2 Years
Andrew BerensLeerink Partners
Success Rate
9/13 ratings generated profit
69%
Average Return
+42.83%
Copying Andrew Berens's trades and holding each position for 2 Years would result in 69.23% of your transactions generating a profit, with an average return of +42.83% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMNM Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
20
21
11
6
5
Buy
10
11
17
15
11
Hold
0
0
0
0
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
30
32
28
21
18
In the current month, IMNM has received 16 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. IMNM average Analyst price target in the past 3 months is 35.33.
Each month's total comprises the sum of three months' worth of ratings.

IMNM Financial Forecast

IMNM Earnings Forecast

Next quarter’s earnings estimate for IMNM is -$0.61 with a range of -$0.71 to -$0.41. The previous quarter’s EPS was -$0.65. IMNM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IMNM has Performed in-line its overall industry.
Next quarter’s earnings estimate for IMNM is -$0.61 with a range of -$0.71 to -$0.41. The previous quarter’s EPS was -$0.65. IMNM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IMNM has Performed in-line its overall industry.

IMNM Sales Forecast

Next quarter’s sales forecast for IMNM is $154.00K with a range of $0.00 to $2.00M. The previous quarter’s sales results were $0.00. IMNM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IMNM has Performed in-line its overall industry.
Next quarter’s sales forecast for IMNM is $154.00K with a range of $0.00 to $2.00M. The previous quarter’s sales results were $0.00. IMNM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IMNM has Performed in-line its overall industry.

IMNM Stock Forecast FAQ

What is IMNM’s average 12-month price target, according to analysts?
Based on analyst ratings, Immunome’s 12-month average price target is 35.33.
    What is IMNM’s upside potential, based on the analysts’ average price target?
    Immunome has 20.26% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IMNM a Buy, Sell or Hold?
          Immunome has a consensus rating of Strong Buy which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Immunome’s price target?
            The average price target for Immunome is 35.33. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $40.00 ,the lowest forecast is $24.00. The average price target represents 20.26% Increase from the current price of $29.38.
              What do analysts say about Immunome?
              Immunome’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of IMNM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.